Beth Schultz Scott, OD has been serving as our Vice President Medical Affairs since October 2020.

From 2019 to 2020 she was CEO/President of Medical Advance Scientific Solutions (MASS) which supports emerging biotech companies in strategic areas of Regulatory Affairs, Clinical Development, Medical Affairs, Reimbursement and Market Access.

Dr. Scott has lead Medical Launch Readiness Initiatives of several innovative companies for ophthalmic pharmaceuticals and medical devices indicated for the treatment of Glaucoma/Ocular Hypertension, Dry Eye, Retinal Diseases, Myopia and Presbyopia. Dr. Scott has generated evidence in preparation for multiple ‘First in Class’ launches of novel investigational candidates.

Between 2015 and 2019 Beth mastered the peri-launch lifecycle through collaboration on several epic teams. At Aerie she introduced both Rhopressa and Rocklatan indicated for treatment of Glaucoma and Ocular Hypertension. At Shire she raised awareness of Xiidra for Dry Eye. Prior to that, Dr. Scott cultivated her skills in Pre-Approval research and Early Phase Pipeline Development. While in Retina, Beth represented Bayer Healthcare on the EYLEA® Global Team as the Physician for Studies to fulfil Regulatory Requirements across several indications including AMD, CRVO, DME, and mCNV. As Medical Director she also contributed to the Brand Roadmap specifically for AMD. She entered industry through Alcon, holding positions of increasing responsibility in Regulatory Affairs over a wide portfolio of medical devices and prescription/OTC pharmaceuticals.

Prior to industry, Beth was a committed faculty member in academia at the Pennsylvania College of Optometry, Salus University educating Optometrists, Audiologists, and Physicians Assistants in Pharmacology. Dr. Scott expanded international ophthalmic education across the EU, Latin America, Asia Pacific and Canada and standardized the practice of Clinical Optometry and development of Eye Health Care as a Founding member of the Hogeschool van Utrecht School of Optometry in The Netherlands. Beth obtained her optometry degree from the Pennsylvania College of Optometry and Masters’ in Clinical Pharmacology at Thomas Jefferson University with a research emphasis in Ocular Oncology focusing on the treatment of Squamous Cell Carcinoma of the Conjunctiva and Choroidal Melanoma at Wills Eye Hospital.